Related Experiment Video
Updated: May 23, 2026
08:40
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
[Phenotypic differences of stroma cells in benign and malignant human prostate tissues]
Hui Zhou1, Hong-bin Sun, Wen-bin Huang
1Department of Urology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210006, China.
Zhonghua Yi Xue Za Zhi
|April 12, 2012
Summary
Prostate cancer stroma cells show distinct phenotypes compared to benign tissues. Increased myofibroblast volume in advanced prostate cancer suggests a role in progression, warranting clinical attention.
Area of Science:
- Urological pathology
- Cancer biology
- Immunohistochemistry
Context:
- Prostate cancer stroma composition differs significantly from benign prostate hyperplasia.
- Understanding these stromal changes is crucial for diagnosing and treating prostate cancer.
Purpose:
- To analyze and differentiate the phenotypic changes in stroma cells between benign and malignant human prostate tissues.
- To quantify stroma volume in early and advanced prostate cancer.
Summary:
- Masson staining and immunohistochemistry revealed distinct myofibroblast phenotypes in prostate cancer (α-SMA+, vimentin+) versus benign prostate (α-SMA+, desmin+).
- Advanced prostate cancer exhibited a significantly higher stroma volume (Grade 2/3) compared to early-stage disease (83% vs. 55%).
Impact:
- Identified significant phenotypic differences in prostate stroma cells between benign and malignant conditions.
- High myofibroblast expression in advanced prostate cancer may drive progression, highlighting its clinical significance and need for vigilance.
